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Abstract
Introduction: Due to the increasing prevalence and severity of invasive candidiasis, investigators have developed
clinical prediction rules to identify patients who may benefit from antifungal prophylaxis or early empiric therapy.
The aims of this study were to validate and compare the Paphitou and Ostrosky-Zeichner clinical prediction rules
in ICU patients in a 689-bed academic medical center.
Methods: We conducted a retrospective matched case-control study from May 2003 to June 2008 to evaluate the
sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of each rule. Cases
included adults with ICU stays of at least four days and invasive candidiasis matched to three controls by age,
gender and ICU admission date. The clinical prediction rules were applied to cases and controls via retrospective
chart review to evaluate the success of the rules in predicting invasive candidiasis. Paphitou’s rule included
diabetes, total parenteral nutrition (TPN) and dialysis with or without antibiotics. Ostrosky-Zeichner’s rule included
antibiotics or central venous catheter plus at least two of the following: surgery, immunosuppression, TPN, dialysis,
corticosteroids and pancreatitis. Conditional logistic regression was performed to evaluate the rules. Discriminative
power was evaluated by area under the receiver operating characteristic curve (AUC ROC).
Results: A total of 352 patients were included (88 cases and 264 controls). The incidence of invasive candidiasis
among adults with an ICU stay of at least four days was 2.3%. The prediction rules performed similarly, exhibiting low
PPVs (0.041 to 0.054), high NPVs (0.983 to 0.990) and AUC ROCs (0.649 to 0.705). A new prediction rule (Nebraska
Medical Center rule) was developed with PPVs, NPVs and AUC ROCs of 0.047, 0.994 and 0.770, respectively.
Conclusions: Based on low PPVs and high NPVs, the rules are most useful for identifying patients who are not
likely to develop invasive candidiasis, potentially preventing unnecessary antifungal use, optimizing patient ICU care
and facilitating the design of forthcoming antifungal clinical trials.
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Introduction
The prevalence of nosocomial invasive candidiasis has
increased dramatically since the 1990s, with Candida spp.
being the fourth most common cause of bloodstream
infections in the United States, accounting for 9% of such
infections, over half of which occur among ICU patients
[1,2]. Some risk factors commonly associated with invasive
candidiasis include prior surgery, acute renal failure,
receipt of total parenteral nutrition (TPN) and presence of
a central venous catheter (CVC) [3]. The clinical and eco-
nomic burden of invasive candidiasis is significant, as
these infections are associated with increased mortality,
longer hospital stay and higher cost [4]. Crude mortality in
patients with candidemia is approximately 40%, with the
highest mortality among those infected with C. krusei
(approaching 60%) and the lowest among those infected
with C. parapsilosis (approaching 30%) [2]. Delayed
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has been associated with increased mortality [5-7].
In an effort to minimize the detrimental effects of
nosocomial candidiasis and delayed appropriate therapy,
prophylactic antifungal therapy has been utilized with
varied results [8]. Some studies of ICU patients have
shown a beneficial effect of antifungal prophylaxis [9-11],
but others have not [12]. Two meta-analyses have shown
conflicting results, one showing decreased mortality with
antifungal prophylaxis [13] and the other showing no
survival advantage [14]. Nevertheless, universal antifungal
prophylaxis is not clinically or fiscally responsible, as
many patients are at low risk for developing infection
and inappropriate use of antifungals can promote resis-
tance and increase costs. Therefore, a prediction rule for
identifying patients most likely to benefit from prophy-
laxis would be advantageous.
In 2005, Paphitou and colleagues [15] published a pre-
diction rule for invasive candidiasis in ICU patients that
incorporated risk factors of hemodialysis, TPN, diabetes
mellitus and broad-spectrum antibiotics. In 2007,
Ostrosky-Zeichner and colleagues [16] sought to improve
upon the previously published rule. They found that a
CVC or broad-spectrum antibiotics in combination with
at least two minor risk factors (pancreatitis, major sur-
gery, TPN, immunosuppressants, corticosteroids or dialy-
sis) was predictive of invasive candidiasis.
Limited data regarding external validation of the
Ostrosky-Zeichner rule exist [17,18], and no published
evidence indicates external validation of the Paphitou
rule. The aim of our study was to evaluate the Paphitou
[15] and Ostrosky-Zeichner [16] clinical prediction rules
and retrospectively validate them in ICU patients at our
institution.
Materials and methods
Population
This study was a retrospective, matched case-control study
conducted at The Nebraska Medical Center, a 689-bed
academic medical center. Cases and controls were eligible
for inclusion if they had an ICU stay of four days or longer
from May 2003 through June 2008 and were at least 18
years old. Exclusion criteria included invasive candidiasis
or receipt of systemic antifungals prior to day 4 of the ICU
stay. Inclusion and exclusion criteria matched those of the
original studies [15,16]. Patients who developed invasive
candidiasis from day 4 of the ICU stay through seven days
after ICU discharge were identified on the basis of clinical
microbiology data and served as the case cohort. Cases
were matched at a 1:3 ratio with patients who did not
develop invasive candidiasis (controls), according to nega-
tive culture results, based on age, gender and ICU admis-
sion date. The overall incidence of invasive candidiasis was
determined by the entire ICU cohort of all patients at least
18 years old with an ICU stay of at least 4 days admitted
during the study period (not limited to cases and controls).
The clinical prediction rules were applied to cases and
controls via retrospective chart review to evaluate the suc-
cess of the rules in predicting invasive candidiasis. The
study was approved by our medical center’s Institutional
Review Board with a complete waiver of informed consent.
Data collection
Invasive candidiasis risk factor data were collected starting
from seven days prior to ICU admission (D-7) through the
third day of ICU stay (D3) and included presence of a
CVC, TPN, hemodialysis, major surgery, pancreatitis,
mechanical ventilation, Acute Physiology and Chronic
Health Evaluation (APACHE) II score (calculated on D1),
history of invasive candidiasis, broad-spectrum antibiotics,
systemic corticosteroids and immunosuppressants. Out-
come data were collected from day 4 of the ICU stay
through 7 days after ICU discharge and included cultures
positive for Candida spp. from blood, peritoneal fluid or
another sterile site. Urine, sputum or bronchial washing
positive for Candida spp. were not considered invasive
candidiasis. The diagnosis of invasive candidiasis was
made based on the revised consensus definitions of inva-
sive fungal infections developed by the European Organi-
zation for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Disease Mycoses Study
Group [19]. More specifically, only those with proven
invasive candidiasis, as demonstrated by recovery of yeast
from a sample obtained from a normally sterile site, were
included as cases. Major surgery was defined as a proce-
dure utilizing general anesthesia. Pancreatitis was identi-
fied using International Classification of Diseases, Ninth
Revision, code 577.0 (acute pancreatitis) as a primary or
secondary discharge diagnosis. From the electronic medi-
cal records, we collected data regarding administration of
medications and TPN; culture, chemistry and hematology
profiles; history of invasive candidiasis; and diabetes. Data
regarding mechanical ventilation, vital signs, surgeries,
ICU discharge date and CVC were collected from the
paper medical records. Discharge disposition and cost of
stay data were collected from the institution’s financial
database.
Clinical prediction rules
The Paphitou rule included receipt of TPN (D-7 to D0),
hemodialysis (D1 to S3) or a history of diabetes mellitus
with or without broad-spectrum antibiotics (D-7 to D3).
For purposes of this study, two Paphitou rules were
evaluated: one without broad spectrum antibiotics and
one with broad spectrum antibiotics (Table 1). The
Ostrosky-Zeichner rule included one of two major risk
factors (CVC (D1 to D3), receipt of broad-spectrum
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tors (TPN (D1 to D3), dialysis (D1 to D3), major surgery
(D-7 to D0), pancreatitis (D-7 to D0), corticosteroids
(D-7 to D3) or immunosuppressants (D-7 to D0)). For
purposes of this study, two Ostrosky-Zeichner rules
were evaluated: one with broad-spectrum antibiotics and
one with a CVC (Table 1).
A breakpoint value was calculated for each clinical pre-
diction rule based on the final regression equation for
each specific clinical prediction rule. The breakpoint
values provide a practical means by which to interpret the
results of each equation after they are applied to an indivi-
dual patient. For example, if the resultant value is below
the breakpoint of the clinical prediction rule, then accord-
ing to the clinical prediction rule, antifungal therapy will
not be recommended, and vice versa.
Statistical analysis
Baseline categorical variables were analyzed using the c
2
test, and continuous variables were analyzed using Stu-
dent’s t-test. Univariate regression was performed to select
risk factors to be entered into the multivariable model.
Risk factors with P < 0.20 in the univariate regression were
selected for the backward elimination stepwise conditional
logistic regression model. Each case and its three controls,
matched on age, gender and ICU admission date, were
used as a stratum in the conditional logistic regression
analysis [20]. The final model included only variables with
P < 0.05. These variables from the final model were used
to construct the equations used for the clinical prediction
rules. An institution-specific clinical prediction rule,
named the Nebraska Medical Center rule (NMC rule),
was developed based on the institutional risk factors
demonstrating statistical significance following the condi-
tional logistic regression modeling. The prediction rules
were applied to our patient population, and the primary
outcomes were sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) of each
of the clinical prediction rules for invasive candidiasis. A
receiver operating characteristic (ROC) curve was gener-
ated for each rule, and the area under the ROC (AUC
ROC) curve was calculated to determine their discrimina-
tive power. SPSS version 17.0 software (SPSS Inc., Chi-
cago, IL, USA) was used for all analyses.
Results
Patient characteristics
From May 2003 through June 2008, 100 cases met our
inclusion criteria. Four of these cases developed invasive
candidiasis prior to day 4 and were excluded. Eight
patients received systemic antifungals prior to day 4 and
were excluded. Eighty-eight cases were included and
matched to controls at a 1:3 ratio, yielding a total of 352
patients. Of these patients, 59% were male, 75.9% were
Caucasian, 9.9% were African-American and the remain-
ing 14.2% were Hispanic or of other ethnic origin. The
mean age of the patient population was 60.3 years (range,
21 to 96 years). The overall incidence of invasive candi-
diasis during the study period for all patients at least
18 years old with an ICU stay of at least 4 days was 23.3
cases per 1,000 ICU patient-years.
Risk factors
Table 2 shows the results of conditional logistic regression
for the occurrence of risk factors in cases versus matched
controls. The following risk factors demonstrated statisti-
cally significant differences: any broad-spectrum antibiotic
use, CVC (D1 to D3), abdominal surgery (D-7 to D3),
immunosuppressants (D-7 to D0), TPN (D1 to D3) and
mean pre-ICU length of stay. These risk factors were used
to derive the institution-specific rule (NMC rule), except
for systemic corticosteroid use, which was used instead of
immunosuppressants because corticosteroid use was more
common, is likely to be more applicable to other popula-
tions and showed a trend toward statistical significance.
Outcomes
The original publications of the prediction rules did not
provide specific equation variables for each rule. Therefore,
on the basis of multivariate analysis of each risk factor, we
derived equations for each prediction rule (Table 3).
Regardless of the statistical significance of the individual
risk factors in our patient population (Table 2), the Paphi-
tou and Ostrosky-Zeichner rules were applied as is to our
study population to calculate the sensitivity, specificity,
PPV, NPV and AUC ROC for our institution (Table 4).
Sensitivity and specificity ranged from approximately 41%
to 74% and 61% to 81%, respectively. The PPV was less
than 5% for all rules except Paphitou 2, at 5.4%, and the
Table 1 Paphitou and Ostrosky-Zeichner clinical prediction rules
a
Rule Criteria
Paphitou 1 ≥1: TPN (D-7 to D0), hemodialysis (D1 to D3), diabetes
Paphitou 2 ≥1: TPN (D-7 to D0), hemodialysis (D1 to D3), diabetes, broad-spectrum antibiotics (D-7 to D3)
Ostrosky-
Zeichner 1
Central venous catheter
(D1 to D3)
and
≥2
TPN (D1 to D3), hemodialysis (D1 to D3), major surgery (D-7 to D0), pancreatitis (D7 to D0),
corticosteroids (D-7 to D3), immunosuppressants (D-7 to D0)
Ostrosky-
Zeichner 2
Broad spectrum
antibiotics (D1 to D3)
aTPN, total parenteral nutrition; D, day of intensive care unit stay. Adapted from [15,16].
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demonstrated a sensitivity of 84.1%, specificity of 60.2%,
PPV of 4.7%, NPV of 99.4% and AUC ROC of 0.770
(Table 4). The rule breakpoint values are shown in Table
4. A significant increase in in-hospital mortality was seen
in patients who developed invasive candidiasis compared
to controls (29.5% vs. 15.2%, odds ratio 2.33, 95% confi-
dence interval, 1.3 to 4.16; P = 0.004). Cases, as compared
to matched controls, had significantly longer mean total
overall hospital stay (45.3 days vs. 17.1 days; P < 0.001)
and higher mean total costs ($151,940.84 vs. $53,355.56;
P < 0.001).
Discussion
As shown in our study, invasive candidiasis is signifi-
cantly associated with increased mortality, longer overall
hospital stay and higher costs. Due to the appreciable
morbidity, mortality and costs associated with invasive
candidiasis and the implications of delayed appropriate
antifungal therapy, the use of clinical prediction rules to
help determine in which high-risk patients prophylactic
antifungal therapy may be beneficial is of interest
[2,4-7]. This study served as an external validation and
comparison of two previously published clinical predic-
tion rules for invasive candidiasis [15,16]. The variables
utilized in this study were applied exactly as published
in the original rules. In our patient population, several
risk factors used in the Paphitou and Ostrosky-Zeichner
rules, including surgery, pancreatitis, hemodialysis and
diabetes, were not shown to have statistically significant
correlations to invasive candidiasis. Conversely, abdom-
inal surgery and pre-ICU length of stay, which are risk
factors that were not used in the Paphitou and
Ostrosky-Zeichner rules, were found to be significantly
associated with invasive candidiasis. These factors were
used in combination with other significant risk factors,
such as the use of broad-spectrum antibiotics, presence
of a CVC and use of TPN and systemic corticosteroids
Table 2 Presence of risk factors in cases versus controls
a
Risk factor (days of ICU stay) All (n = 352) n (%) Cases (n = 88) n (%) Controls (n = 264)
n (%)
P value OR (95% CI)
Broad-spectrum antibiotics (-7 to 0) 80 (22.7) 30 (34.1) 50 (18.9) 0.005 2.21 (1.29 to 3.79)
Broad-spectrum antibiotics (1 to 3) 296 (84.1) 85 (96.6) 211 (79.9) < 0.001 7.12 (2.17 to 23.4)
Broad-spectrum antibiotics (-7 to 3) 298 (84.7) 85 (96.6) 213 (80.7) < 0.001 6.74 (2.06 to 22.33)
Central venous catheter (1 to 3) 272 (77.3) 81 (92) 191 (72.3) < 0.001 4.42 (1.95 to 10.02)
Surgery (-7 to 0) 40 (11.4) 11 (12.5) 29 (11) 0.700 1.16 (0.55 to 2.43)
Surgery (-7 to 3) 224 (63.6) 62 (70.5) 162 (61.4) 0.159 1.50 (0.89 to 2.53)
Abdominal surgery (-7 to 3) 92 (26.1) 40 (45.5) 52 (19.7) < 0.001 3.40 (2.02 to 5.70)
Immunosuppressants (-7 to 0) 38 (10.8) 15 (17) 23 (8.7) 0.045 2.15 (1.07 to 4.34)
Pancreatitis (-7 to 3) 6 (1.7) 2 (2.3) 4 (1.5) 0.642 1.51 (0.27 to 8.40)
TPN (1 to 3) 69 (19.6) 33 (37.5) 36 (13.6) < 0.001 3.80 (2.18 to 6.63)
Dialysis (1 to 3) 32 (9.1) 10 (11.4) 22 (8.3) 0.396 1.41 (0.64 to 3.11)
Systemic corticosteroids (-7 to 3) 134 (38.1) 41 (46.6) 93 (35.2) 0.076 1.60 (0.98 to 2.62)
Diabetes 101 (28.7) 26 (29.5) 75 (28.4) 0.892 1.06 (0.62 to 1.80)
Mechanical ventilation (-7 to 3) 210 (59.7) 56 (63.6) 154 (58.3) 0.413 1.23 (0.75 to 2.03)
Mean APACHE II score, day 1 (± SD) 15.9 (9.5) 17.0 (8.8) 15.5 (9.7) 0.195 1.03 (0.99 to 1.06)
Mean pre-ICU LOS, days (± SD) 1.7 (0.24) 3 (7.3) 1.3 (3.0) 0.036 1.08 (1.01 to 1.14)
OR, odds ratio; CI, confidence interval; TPN, total parenteral nutrition; APACHE, Acute Physiology and Chronic Health Evaluation; LOS, length of stay.
Table 3 Prediction rule equations
a
Rule Equation
Paphitou
1
(0.092 × diabetes) + (1.445 × TPN D-7 to D0) + (0.46 × HD D1 to D3)
Paphitou
2
(0.065 × diabetes) + (1.352 × TPN D-7 to D0) + (0.436 × HD D1 to D3) + (0.523 × BSAbx D-7 to D3)
Ostrosky
1
(1.465 × BSAbx D1 to D3) + (-0.188 × surgery D-7 to D0) + (0.769 × immunosuppression D-7 to D0) + (1.41 × TPN D1 to D3) + (0.524 ×
HD1 to HD3) + (0.342 × steroid D-7 to D3)
Ostrosky
2
(1.116 × CVC D1 to D3) + (-0.183 × surgery D-7 to D0) + (0.782 × immunosuppression D-7 to D0) + (1.408 × TPN D1 to D3) + (0.468 ×
HD D1 to D3) + (0.377 × steroid D-7 to D3)
NMC (1.537 × BSAbx D1 to D3) + (0.873 × CVC D1 to D3) + (0.922 × TPN D1 to D3) + (0.402 × steroid D-7 to D3) + (0.879 × abdominal
surgery) + (0.039 × pre-ICU LOS)
aTPN, total parenteral nutrition; HD, hemodialysis; BSAbx, broad-spectrum antibiotics; CVC, central venous catheter; NMC, Nebraska Medical Center; LOS, length of
stay.
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population.
The Paphitou and Ostrosky-Zeichner prediction rules
performed similarly. Paphitou rule 1, involving the fewest
risk factors, demonstrated the lowest sensitivity but the
highest specificity. As the rules utilized more risk factors,
the sensitivity increased with a corresponding drop in spe-
cificity. The NMC rule demonstrated a higher sensitivity
than and similar specificity to the Ostrosky-Zeichner rule
with the same number of risk factors used in the rule
(Tables 3 and 4). Depending on the rule, only 4.1% to
5.4% of patients meeting rule criteria developed invasive
c a n d i d i a s i s .T h i sl o wP P Vs u g g e s t sal i m i t e dr o l ef o rt h e
prediction rules in identifying patients most likely to bene-
fit from antifungal prophylaxis in the ICU. Because of a
relatively low overall incidence of invasive candidiasis, all
of the prediction rules had a low PPV, which means that if
the NMC rule had been applied to our study population,
the percentage of ICU patients who would have received
antifungal prophylaxis would have been 4.7%. In contrast,
the rules demonstrated a high NPV. The NPVs indicate
that fewer than 2% (fewer than 1% under the NMC rule)
of patients not meeting rule criteria developed invasive
candidiasis. This suggests that when the rule equations are
applied to a patient, if the resultant value is below the rule
breakpoint (Table 4), the patient will not likely develop
invasive candidiasis (for example, a probability of 99%
using the NMC rule) and therefore will not benefit from
antifungal prophylaxis.
Paphitou’s rule was developed in 2005 on the basis of a
study of 327 patients in a surgical ICU [15]. The overall
incidence of invasive candidiasis in the Paphitou study
was 7.1%, which is higher than the observed overall inci-
dence of 2.3% in our study. However, our study was not
conducted exclusively in a surgical ICU population.
Direct comparison of the sensitivity, specificity, PPV and
NPV is not possible, because these values were not
reported in the Paphitou study.
In 2007, Ostrosky-Zeichner and colleagues [16]
expanded on the results of the Paphitou study to include
a broader range of risk factors in both medical and surgi-
cal ICU patients in a multicenter study of nearly 3,000
patients. In contrast to the Paphitou study, the overall
incidence of invasive candidiasis among the Ostrosky-
Zeichner population, at 3%, was more similar to that of
our patient population. Likewise, the Ostrosky-Zeichner
patient population was more comparable to ours in that
medical and surgical ICU patients were included. Sensi-
tivity and specificity were 34% and 90%, respectively, and
the PPV and NPV were 1% and 97%, respectively. In
comparison, our study demonstrated higher sensitivity,
PPV and NPV, but lower specificity.
More recently, Ostrosky-Zeichner and colleagues [17]
further refined their rule in a retrospective study of 597
ICU patients by including the combination of mechani-
cal ventilation for at least 48 hours and the presence of
a CVC and broad-spectrum antibiotic use on D1 to D3
plus an additional minor risk factor and found that this
changed the sensitivity, specificity, PPV and NPV to
50%, 83%, 10% and 97%, respectively. The investigators
also applied their original rule to this patient population
and found a sensitivity and specificity of 27% and 93%,
respectively, and a PPV and NPV of 13% and 97%,
respectively. In comparison, our study demonstrated
higher sensitivity and NPV, but lower specificity and
PPV. The overall incidence of invasive candidiasis in the
Ostrosky-Zeichner population was 3.7%. Notably, 80% of
patients in the Ostrosky-Zeichner study were surgical
ICU patients, and 78% of them were mechanically venti-
lated in comparison to approximately 60% who were
mechanically ventilated in our study. Moreover,
mechanical ventilation was not found to be significantly
different among cases and controls in our study popula-
tion (Table 2). Because our study was completed before
the new rule was published, comparison of the sensitiv-
ity, specificity, PPV and NPV of this rule in our patient
population was not possible.
Notably, a large number of solid organ and hemato-
poietic stem cell transplants are performed at our insti-
tution. Because the specific equations used in the
Paphitou and Ostrosky-Zeichner studies were not
reported, we had to derive our own equations for their
rules. Our patient population’s characteristics may have
caused various factors, such as use of immunosuppres-
sants, systemic corticosteroids and broad-spectrum anti-
biotics, to be weighted differently in the equations for
the rules. Consequently, these factors might have chan-
ged the performance of the rules.
Table 4 Comparison of prediction rules
a
Rule Sensitivity Specificity PPV NPV AUC ROC Rule break point
Paphitou 1 0.409 0.811 0.048 0.983 0.649 0.506
Paphitou 2 0.456 0.811 0.054 0.984 0.692 0.556
Ostrosky 1 0.659 0.640 0.041 0.988 0.698 1.68
Ostrosky 2 0.739 0.606 0.042 0.990 0.705 1.14
NMC 0.841 0.602 0.047 0.994 0.770 2.45
aPPV, positive predictive value; NPV, negative predictive value; AUC ROC, area under the receiver operating characteristic curve; NMC, Nebraska Medical Center.
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power of the rule. A value of 1 would be equivalent to
perfect discriminative power; that is, the higher and clo-
ser a value is to unity, the better the rule discriminates
patients with invasive candidiasis from patients without
invasive candidiasis. Paphitou rule 1, incorporating the
fewest risk factors, achieved the lowest AUC ROC curve
and therefore the lowest discriminative power. Our insti-
t u t i o n - s p e c i f i cr u l eh a dt h eh i g h e s tA U CR O Cc u r v ea t
0.770, indicating the best discriminative power among
the various rules.
Playford et al. [18] recently evaluated three clinical
prediction rules in a prospective cohort of 615 Austra-
lian ICU patients. The rules evaluated included the 2007
and 2011 Ostrosky-Zeichner rules plus an additional
rule that included Candida colonization [16,17,21]. Fun-
gal surveillance cultures of the throat, rectum and/or
perineum and urine were performed 72 hours after ICU
admission and twice weekly thereafter, enabling the
investigators to add Candida colonization as a factor to
the two Ostrosky-Zeichner rules. The overall incidence
of invasive candidiasis in their study was 2.4%, which is
similar to the incidence in our study. However, mechan-
ical ventilation, CVC use and surgical procedures were
more common and systemic corticosteroid and immu-
nosuppressant use were less common in their study
than in our patient population. Their study demon-
strated that the specificities and PPVs of the two
Ostrosky-Zeichner rules were improved by the addition
of colonization to the rule, although this resulted in
lower sensitivity.
Our study has several limitations. First, the study was a
retrospective, single-center study. Additionally, our insti-
tution has a large population of solid organ transplant
and hematopoietic stem cell transplant patients. Thus,
the results of our study may not be generalizable to those
conducted at other institutions. Data from our study as
well as that of Playford et al. [18] suggest that clinical
prediction rules can be applied only to patient popula-
tions other than the derivation population if the potential
for case-mix variability is taken into consideration. The
application of the rules was limited to ICU patients, as
this was the original population for which the rules were
developed. The development and application of a predic-
tion rule for use in the non-ICU patient population
remains an unaddressed issue. Also, previous studies sup-
porting the effectiveness of antifungal prophylaxis were
conducted in populations that had an incidence of inva-
sive candidiasis over 10% among the control populations
[9-11]. In contrast, our study, along with those in which
the Ostrosky-Zeichner and Paphitou rules were devel-
oped [15-17], occurred in populations with lower infec-
tion rates. In this setting, it may be more appropriate to
focus attention on early empiric antifungal therapy,
although early empiric therapy with fluconazole was
not shown to be beneficial in an ICU population with an
incidence of invasive candidiasis of 9% in the control
population [22]. Last, clinical prediction rules utilizing
colonization with Candida spp. as a risk factor [21,23]
could not be evaluated in our study, because routine
surveillance cultures to detect such colonization are not
performed at our institution. While colonization has
been shown to be a risk factor for invasive candidiasis
[24], the predictive value of colonization for invasive
candidiasis is variable [21,23,25].
Conclusions
Invasive candidiasis is a serious and devastating infection
leading to a significant clinical and economic burden on
patients and healthcare systems. The best method for
identifying patients who are likely to benefit from antifun-
gal prophylaxis remains unclear. Clinical prediction rules
incorporating numerous risk factors have been developed
and externally applied. A new clinical prediction rule, the
NMC rule, using factors that are easily obtained, was
developed on the basis of our experience in our patient
population and compared favorably to the previously pub-
lished rules. We intend to validate this rule in a prospec-
tive study at our institution. Because of the high NPV, the
rules are likely best applied to identify patients who would
least likely benefit from antifungal prophylaxis rather than
to identify patients who should receive such therapy.
Future studies should investigate the prospective applica-
tion of these clinical prediction rules in an attempt to pre-
vent unnecessary antifungal therapy, optimize care for
patients and facilitate the design of forthcoming antifungal
clinical trials.
Key messages
￿ The prevalence of nosocomial invasive candidiasis
has increased and is associated with increased mortal-
ity, longer hospital stay and higher costs. Further,
delays in appropriate therapy have been associated
with increased mortality due to invasive candidiasis.
￿ Universal antifungal prophylaxis is not clinically or
fiscally responsible, as many patients are at low risk
for developing infection, and inappropriate use of
antifungals can promote resistance and increase
costs. Therefore, a prediction rule for identifying
patients most likely to benefit from prophylaxis
would be advantageous.
￿ This study serves as an external validation and com-
parison of two clinical prediction rules for invasive
candidiasis previously published by Paphitou et al.
[15] and Ostrosky-Zeichner et al. [16]. A new clinical
prediction rule, the NMC rule, using factors that are
easily obtained, was developed on the basis of our
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favorably to the previously published rules.
￿ Due to the high NPVs, the rules are likely best
applied to identify patients who would be least likely
to benefit from antifungal prophylaxis rather than to
identify patients who should receive such therapy.
￿ Future studies should investigate the prospective
application of these clinical prediction rules in an
attempt to prevent unnecessary antifungal therapy,
optimize care for patients and facilitate the design of
forthcoming antifungal clinical trials.
Abbreviations
AUC ROC: area under the receiver operating characteristic curve; CVC: central
venous catheter; NPV: negative predictive value; PPV: positive predictive
value; TPN: total parenteral nutrition.
Acknowledgements
This study was supported by a research grant from Pfizer. The funding body
did not have any role in the study design; the collection, analysis and
interpretation of data; manuscript preparation; or the decision to submit the
manuscript for publication.
Author details
1Department of Pharmaceutical & Nutrition Care, The Nebraska Medical
Center, 981090 Nebraska Medical Center, Omaha, NE 68198-1090, USA.
2Section of Infectious Diseases, Department of Internal Medicine, College of
Medicine, University of Nebraska Medical Center, 985400 Nebraska Medical
Center, Omaha, NE 68198-5400, USA.
3Department of Pharmacy Practice,
College of Pharmacy, University of Nebraska Medical Center, 986045
Nebraska Medical Center, Omaha, NE 68198-6045, USA.
Authors’ contributions
EDH contributed to the study concept and design, the execution of the
study and manuscript preparation. MKZ and MM contributed to data
acquisition and manuscript preparation. MER and AGF contributed to the
study design and manuscript preparation. ACK contributed to the study
design, statistical analysis and manuscript preparation. All authors read and
approved the final manuscript.
Competing interests
EDH is currently an employee of Cubist Pharmaceuticals; is a shareholder in
Cubist Pharmaceuticals; has been a consultant for Ortho-McNeil
Pharmaceuticals, Cubist Pharmaceuticals and Forest Laboratories; and has
received research funding from Pfizer and TheraDoc. MER has received
research funding from Cubist Pharmaceuticals, Sanofi-Pasteur, Cardinal
Health Foundation, 3 M and Molynlcke. AGF has received research funding
from Merck and Pfizer. MKZ, MM and ACK have no conflicts of interest to
declare.
Received: 8 March 2011 Revised: 9 July 2011 Accepted: 9 August 2011
Published: 9 August 2011
References
1. Fridkin SK, Jarvis WR: Epidemiology of nosocomial fungal infections. Clin
Microbiol Rev 1996, 9:499-511.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB:
Nosocomial bloodstream infections in US hospitals: analysis of 24,179
cases from a prospective nationwide surveillance study. Clin Infect Dis
2004, 39:309-317.
3. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA,
Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP, National
Epidemiology of Mycoses Survey (NEMIS) Study Group: Risk factors for
candidal bloodstream infections in surgical intensive care unit patients:
the NEMIS prospective multicenter study. The National Epidemiology of
Mycosis Survey. Clin Infect Dis 2001, 33:177-186.
4. Rentz AM, Halpern MT, Bowden R: The impact of candidemia on length
of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998,
27:781-788.
5. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT:
Time to initiation of fluconazole therapy impacts mortality in patients
with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31.
6. Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of
Candida bloodstream infection until positive blood culture results are
obtained: a potential risk factor for hospital mortality. Antimicrob Agents
Chemother 2005, 49:3640-3645.
7. Nolla-Salas J, Sitges-Serra A, León-Gil C, Martínez-González J, León-
Regidor MA, Ibáñez-Lucia P, Torres-Rodríguez JM: Candidemia in non-
neutropenic critically ill patients: analysis of prognostic factors and
assessment of systemic antifungal therapy. Study Group of Fungal
Infection in the ICU. Intensive Care Med 1997, 23:23-30.
8. Cruciani M, de Lalla F, Mengoli C: Prophylaxis of Candida infections in
adult trauma and surgical intensive care patients: a systematic review
and meta-analysis. Intensive Care Med 2005, 31:1479-1487.
9. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, Chiolero R,
Pannatier A, Schilling J, Geroulanos S, Glauser MP, Calandra T: Fluconazole
prophylaxis prevents intra-abdominal candidiasis in high-risk surgical
patients. Crit Care Med 1999, 27:1066-1072.
10. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D:
Prevention of severe Candida infections in nonneutropenic, high-risk,
critically ill patients: a randomized, double-blind, placebo-controlled trial
in patients treated by selective digestive decontamination. Intensive Care
Med 2002, 28:1708-1717.
11. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J,
Lipsett PA: Double-blind placebo-controlled trial of fluconazole to
prevent candidal infections in critically ill surgical patients. Ann Surg
2001, 233:542-548.
12. Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L: Routine
prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin)
in nontransplant/nonburned critically ill surgical and trauma patients.
J Trauma 1994, 36:20-26.
13. Playford EG, Webster AC, Sorrell TC, Craig JC: Antifungal agents for
preventing fungal infections in non-neutropenic critically ill and surgical
patients: systematic review and meta-analysis of randomized clinical
trials. J Antimicrob Chemother 2006, 57:628-638.
14. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH: Fluconazole
prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med
2005, 33:1928-1936.
15. Paphitou NI, Ostrosky-Zeichner L, Rex JH: Rules for identifying patients at
increased risk for candidal infections in the surgical intensive care unit:
approach to developing practical criteria for systematic use in antifungal
prophylaxis trials. Med Mycol 2005, 43:235-243.
16. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V,
Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG,
Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH:
Multicenter retrospective development and validation of a clinical
prediction rule for nosocomial invasive candidiasis in the intensive care
setting. Eur J Clin Microbiol Infect Dis 2007, 26:271-276.
17. Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C,
Wood C, Sobel JD: Improvement of a clinical prediction rule for clinical
trials on prophylaxis for invasive candidiasis in the intensive care unit.
Mycoses 2011, 54:46-51.
18. Playford EG, Lipman J, Kabir M, McBryde ES, Nimmo GR, Lau A, Sorrell TC:
Assessment of clinical risk predictive rules for invasive candidiasis in a
prospective multicentre cohort of ICU patients. Intensive Care Med 2009,
35:2141-2145.
19. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T,
Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW,
Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW,
Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A,
Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T,
Bennett JE, European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group; National Institute of Allergy
and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus
Group: Revised definitions of invasive fungal disease from the European
Organization for Research and Treatment of Cancer/Invasive Fungal
Infections Cooperative Group and the National Institute of Allergy and
Hermsen et al. Critical Care 2011, 15:R198
http://ccforum.com/content/15/4/R198
Page 7 of 8Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus
Group. Clin Infect Dis 2008, 46:1813-1821.
20. Rothman KJ, Greenland S, Lash TL: Modern Epidemiology. 3 edition.
Philadelphia Lippincott Williams & Wilkins; 2008.
21. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R: Candida
colonization and subsequent infections in critically ill surgical patients.
Ann Surg 1994, 220:751-758.
22. Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW,
Hadley S, Slotman G, Panzer H, Biswas P, Rex JH: Empirical fluconazole
versus placebo for intensive care unit patients: a randomized trial. Ann
Intern Med 2008, 149:83-90.
23. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-
Lerma F, Garnacho-Montero J, León MA, EPCAN Study Group: A bedside
scoring system (”Candida score”) for early antifungal treatment in
nonneutropenic critically ill patients with Candida colonization. Crit Care
Med 2006, 34:730-737.
24. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Risk factors for
hospital-acquired candidemia: a matched case-control study. Arch Intern
Med 1989, 149:2349-2353.
25. Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Hammond JM,
Hendrix CW: The diagnostic value of fungal surveillance cultures in
critically ill patients. Surg Infect (Larchmt) 2000, 1:273-281.
doi:10.1186/cc10366
Cite this article as: Hermsen et al.: Validation and comparison of clinical
prediction rules for invasive candidiasis in intensive care unit patients: a
matched case-control study. Critical Care 2011 15:R198.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hermsen et al. Critical Care 2011, 15:R198
http://ccforum.com/content/15/4/R198
Page 8 of 8